TABLE 1.

Shifts from baseline to worst value during study for hemoglobin, platelets, and neutrophils in linezolid phase III comparator-controlled trials^a

Group (shift category)	% (no. shifted/total no.) for:
	All treatment durations in:		Treatment durations greater than 2 weeks in:
	Linezolid group	Comparator group	Linezolid group	Comparator group
Hemoglobin
Any shift	6.6 (118/1785)	6.4 (110/1726)	9.0 (64/708)	6.5 (43/662)
Shift of 1 grade	5.3 (95/1785)	5.3 (91/1726)	7.8 (55/708)	5.3 (35/662)
Shift of 2 grades	0.8 (15/1785)	0.6 (11/1726)	0.7 (5/708)	0.9 (6/662)
Shift of 3 grades	0.2 (4/1785)	0.2 (4/1726)	0.1 (1/708)	0.3 (2/662)
Shift of 4 grades	0.2 (4/1785)	0.2 (4/1726)	0.4 (3/708)	0
Platelet
Any shift	2.9 (36/1243)	1.6 (19/1174)	4.1 (19/461)	1.0 (4/403)
Shift of 1 grade	1.4 (18/1243)	0.9 (10/1174)	2.0 (9/461)	0.7 (3/403)
Shift of 2 grades	1.1 (14/1243)	0.5 (6/1174)	1.5 (7/461)	0.2 (1/403)
Shift of 3 grades	0.3 (4/1243)	0.3 (3/1174)	0.7 (3/461)	0
Shift of 4 grades	0	0	0	0
Neutrophil
Any shift	3.3 (55/1673)	3.4 (54/1612)	4.7 (31/664)	3.7 (23/622)
Shift of 1 grade	2.5 (41/1673)	2.3 (37/1612)	3.5 (23/664)	3.1 (19/622)
Shift of 2 grades	0.4 (7/1673)	0.7 (11/1612)	0.6 (4/664)	0.3 (2/622)
Shift of 3 grades	0.3 (5/1673)	0.2 (3/1612)	0.5 (3/664)	0
Shift of 4 grades	0.1 (2/1673)	0.2 (3/1612)	0.2 (1/664)	0.3 (2/622)

^aAIDS Clinical Trial Group criteria (15).